Phase 1 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give written consent to participate
- People aged 18 to 70 years, of any sex
- People whose organ function (such as liver and kidneys) meets the required health levels at screening
- People who test positive for a protein called CD19 (a marker found on certain immune cells)
- For the lupus (SLE) group: People who were diagnosed with SLE at least 6 months before the screening visit
- For the lupus (SLE) group: People who test positive for certain immune markers in their blood (antinuclear antibody, anti-dsDNA antibody, and/or anti-Smith antibody) at screening
- For the lupus (SLE) group: People whose SLE has come back after treatment or has not responded to previous treatments
- For the muscle inflammation (IIM) group: People who were diagnosed with inflammatory muscle disease before the screening visit
- For the muscle inflammation (IIM) group: People who test positive for certain antibodies related to muscle inflammation at screening
- For the muscle inflammation (IIM) group: People whose muscle inflammation condition has come back after treatment or has not responded to previous treatments
Who may not be able to join:
- People who have an active infection, such as hepatitis or tuberculosis
- People who have other autoimmune diseases (besides the condition being studied)
- People who have serious underlying health conditions, such as cancer or diabetes that is not well controlled
- People who are currently pregnant or breastfeeding
- People who have previously had a major organ transplant (such as a heart, liver, or kidney transplant)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence, severity, and type of treatment-emergent adverse events (TEAEs); Incidence of dose-limiting toxicity (DLT); Maximum concentration (Cmax) in peripheral blood; Time of maximum concentration (Tmax) in peripheral blood; Area under the concentration-time curve (AUC) in peripheral blood; Recommended Dose regimen finding
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.